Sunday, October 2nd, 2022 14:25:12

The phase-3 trials of Covaxin ensure unparalleled safety against the Covid-19 virus with: 93% efficacy against severe Covid-19 disease, reducing hospitalizations; 78% efficacy against mild, moderate, and severe Covid-19 disease

Updated: July 3, 2021 1:56 pm

Comments are closed here.

Archives

Categories